BACKGROUND: The novel human coronavirus SARS-CoV-2 is a major ongoing global threat with huge economic burden. Like all respiratory viruses, SARS-CoV-2 initiates infection in the upper respiratory tract (URT). Infected individuals are often asymptomatic, yet highly infectious and readily transmit virus. A therapy that restricts initial replication in the URT has the potential to prevent progression of severe lower respiratory tract disease as well as limiting person-to-person transmission. METHODS: SARS-CoV-2 Victoria/01/2020 was passaged in Vero/hSLAM cells and virus titre determined by plaque assay. Challenge virus was delivered by intranasal instillation to female ferrets at 5.0 × 106 pfu/ml. Treatment groups received intranasal INNA-051, developed by Ena Respiratory. SARS-CoV-2 RNA was detected using the 2019-nCoV CDC RUO Kit and QuantStudio™ 7 Flex Real-Time PCR System. Histopathological analysis was performed using cut tissues stained with haematoxylin and eosin (H&E). FINDINGS: We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2 ferret infection model effectively reduces levels of viral RNA in the nose and throat. After 5 days post-exposure to SARS-CoV-2, INNA-051 significantly reduced virus in throat swabs (p=<0.0001) by up to a 24 fold (96% reduction) and in nasal wash (p=0.0107) up to a 15 fold (93% reduction) in comparison to untreated animals. INTERPRETATION: The results of our study support clinical development of a therapy based on prophylactic TLR2/6 innate immune activation in the URT, to reduce SARS-CoV-2 transmission and provide protection against COVID-19. FUNDING: This work was funded by Ena Respiratory, Melbourne, Australia.
BACKGROUND: The novel human coronavirus SARS-CoV-2 is a major ongoing global threat with huge economic burden. Like all respiratory viruses, SARS-CoV-2 initiates infection in the upper respiratory tract (URT). Infected individuals are often asymptomatic, yet highly infectious and readily transmit virus. A therapy that restricts initial replication in the URT has the potential to prevent progression of severe lower respiratory tract disease as well as limiting person-to-person transmission. METHODS:SARS-CoV-2 Victoria/01/2020 was passaged in Vero/hSLAM cells and virus titre determined by plaque assay. Challenge virus was delivered by intranasal instillation to female ferrets at 5.0 × 106 pfu/ml. Treatment groups received intranasal INNA-051, developed by Ena Respiratory. SARS-CoV-2 RNA was detected using the 2019-nCoV CDC RUO Kit and QuantStudio™ 7 Flex Real-Time PCR System. Histopathological analysis was performed using cut tissues stained with haematoxylin and eosin (H&E). FINDINGS: We show that prophylactic intra-nasal administration of the TLR2/6 agonist INNA-051 in a SARS-CoV-2ferretinfection model effectively reduces levels of viral RNA in the nose and throat. After 5 days post-exposure to SARS-CoV-2, INNA-051 significantly reduced virus in throat swabs (p=<0.0001) by up to a 24 fold (96% reduction) and in nasal wash (p=0.0107) up to a 15 fold (93% reduction) in comparison to untreated animals. INTERPRETATION: The results of our study support clinical development of a therapy based on prophylactic TLR2/6innate immune activation in the URT, to reduce SARS-CoV-2 transmission and provide protection against COVID-19. FUNDING: This work was funded by Ena Respiratory, Melbourne, Australia.
Authors: M Buschle; W Schmidt; W Zauner; K Mechtler; B Trska; H Kirlappos; M L Birnstiel Journal: Proc Natl Acad Sci U S A Date: 1997-04-01 Impact factor: 11.205
Authors: Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier Journal: N Engl J Med Date: 2012-10-17 Impact factor: 91.245
Authors: N S Zhong; B J Zheng; Y M Li; Z H Xie; K H Chan; P H Li; S Y Tan; Q Chang; J P Xie; X Q Liu; J Xu; D X Li; K Y Yuen; Y Guan Journal: Lancet Date: 2003-10-25 Impact factor: 79.321
Authors: Kuiama Lewandowski; Yifei Xu; Steven T Pullan; Sheila F Lumley; Dona Foster; Nicholas Sanderson; Alison Vaughan; Marcus Morgan; Nicole Bright; James Kavanagh; Richard Vipond; Miles Carroll; Anthony C Marriott; Karen E Gooch; Monique Andersson; Katie Jeffery; Timothy E A Peto; Derrick W Crook; A Sarah Walker; Philippa C Matthews Journal: J Clin Microbiol Date: 2019-12-23 Impact factor: 5.948
Authors: Vicente Javier Clemente-Suárez; Domingo Jesús Ramos-Campo; Juan Mielgo-Ayuso; Athanasios A Dalamitros; Pantelis A Nikolaidis; Alberto Hormeño-Holgado; Jose Francisco Tornero-Aguilera Journal: Nutrients Date: 2021-06-03 Impact factor: 5.717
Authors: Georgia Deliyannis; Chinn Yi Wong; Hayley A McQuilten; Annabell Bachem; Michele Clarke; Xiaoxiao Jia; Kylie Horrocks; Weiguang Zeng; Jason Girkin; Nichollas E Scott; Sarah L Londrigan; Patrick C Reading; Nathan W Bartlett; Katherine Kedzierska; Lorena E Brown; Francesca Mercuri; Christophe Demaison; David C Jackson; Brendon Y Chua Journal: JCI Insight Date: 2021-03-08